Abstract: The present invention relates to a method for producing a coffee blend and the coffee blend obtained by this method, wherein the coffee blend is characterized in that a coffee drink brewed from said coffee blend contains high amounts of chlorogenic acids (CGA) and N-methylpyridinium cations (NMP) and optionally, low amounts of carboxylic acid-5-hydroxytryptamides (C5-HT), has a superior antioxidative activity.

Abstract: The present invention relates to a method for producing a coffee blend and the coffee blend obtained by this method, wherein the coffee blend is characterized in that a coffee drink brewed from said coffee blend contains high amounts of chlorogenic acids (CGA) and N-methylpyridinium cations (NMP) and optionally, low amounts of carboxylic acid-5-hydrox-ytryptamides (C5-HT), has a superior antioxidative activity.

Abstract: This invention relates to the use of 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl)urea (hereinafter also referred to as HECNU) for treatment of pancreatic carcinomas, soft tissue sarcomas, testicular tumors, lymphomas, thymomas, Wilms' tumors, renal carcinomas, melanomas, lung tumors, intracerebral metastases, tumors in the head and neck area and mammary carcinomas.

Abstract: The present invention relates to novel indigoid binsindole derivatives which can be used for the manufacture of a medicament for the treatment of solid cancers.

Abstract: The present invention relates to hydroxylated indirubin derivatives having the formula (I) wherein the group R represents a straight-chain or branched-chain alkyl group or a straight chain or branched-chain alkoxy group each having 1 to 18 carbon atoms, the group R? represents H, a straight-chain or branched-chain alkyl group having 1 to 4 carbon atoms or a glucuronide group, and X is H or OH; which can be used for the manufacture of a medicament for the treatment of solid cancers and leukemia and metastases thereof.

Abstract: Compounds of the general formula (I) and their acid addition salts are provided wherein: R1 signifies a piperazino, p-phenylenediamino, a 2,5-diazabicyclo-[2.2.1]-heptane, a 2,5-diazabicyclo-[2.2.2]-octane radical or a 3,8-diazabicyclo-[3.2.1]-octane radical, which in each case can be substituted with at least one substituent, R2, R4, which are in each case the same, signify a pyrrolidino, thiazolidino, oxazolidino or imidazolidino radical, which in each case can be substituted with at least one substituent, and R3 signifies an alkyl, alkoxy, alkylmercapto or an alkylamino radical, which in each case can be substituted with at least one substituent. These pteridine derivatives are suitable for the inhibition of phosphodiesterases and therefore for the prophylaxis and/or treatment of thrombo-embolic, neurodegenerative diseases, inflammatory diseases, asthmatic diseases as well as hemato-oncological diseases.

Abstract: The present invention relates to the use of cell membrane penetrating indigoid bisindole derivatives for the manufacture of a medicament for the treatment of human solid cancers.

Abstract: Steroid-N-(2-halogen ethyl)-N-nitroso-carbamoylamino acid or peptide esters of the general formula: ##STR1## where R.sub.1 and R.sub.2, which may be identical or different, mean the radical of an amino acid beyond the C atom in the beta position (if present), R.sub.3 means the radical of a steroid or a stilbene derivative pharmacologically similar in action, n is a number from 0-5 and Hal stands for chlorine or fluorine, as well as the method for preparing them by the conversion of an appropriate carbamoyl-amino acid or carbamoyl-peptide in a manner known per se with steroid alcohols or the conversion of steroid-amino acid or steroid-peptide esters with corresponding N-nitroso-carbamoylation or corresponding N-nitroso-carbamoyl-amino acids or peptides in a manner known per se.

Abstract: Steroid-N-(2-halogen ethyl)-N-nitroso-carbamoyl-amino acid or peptide esters of the general formula: ##STR1## where R.sub.1 and R.sub.2, which may be identical or different, mean the radical of an amino acid beyond the C atom in the beta position (if present), R.sub.3 means the radical of a steroid or a stilbene derivative pharmacologically similar in action, n is a number from 0-5 and Hal stands for chlorine or fluorine, as well as the method for preparing them by the conversion of an appropriate carbamoyl-amino acid or carbamoyl-peptide in a manner known per se with steroid alcohols or the conversion of steroid-amino acid or steroid-peptide esters with corresponding N-nitroso-carbamoylation or corresponding N-nitroso-carbamoyl-amino acids or peptides in a manner known per se.

Abstract: This invention relates to compounds having the formula: ##STR1## wherein R.sub.1 and R.sub.2 are selected from the group consisting of hydrogen, acyl, trifluoroacetyl, straight chained and branched alkyl groups with up to 6 carbon atoms, such alkyl groups with up to 3 substituents selected from the group consisting of OH, OSO.sub.2 CH.sub.3, COOH, COOR, CONH.sub.2 and Hal, where R is an alkyl group with up to 6 carbon atoms, and R.sub.1 and R.sub.2 together form a heterocyclic ring containing 4 to 6 carbon atoms and optionally further heteroatoms and such rings with up to 3 substituents selected from the group consisting of lower alkyl, OH, COOH, COOR, CONH.sub.2, where R has the above meaning, the chloroethyl nitrosoureido group and Hal, and Hal is selected from the group consisting of chlorine and fluorine, which heterocyclic ring is not the para-methyl piperazine group, said nitroso ureas having a tumor inhibiting effect.

Abstract: The invention relates to the preparation of novel N-substituted alkyl-N-nitrosocarbamoyl azides and to the compounds obtained thereby. The novel N-substituted alkyl-N-nitrosocarbamoyl azides can be reacted with amines, diamines, aminoalcohols, aminoacids or aminoacid derivatives to prepare unsymmetrically 1,3-disubstituted nitrosoureas which show therapeutical activity.

Abstract: The invention relates to the preparation of unsymmetrically 1,3-disubstituted nitroso ureas from the corresponding N-substituted alkyl-N-nitrosocarbamoyl azide which is reacted with an amine, a diamine, an aminoalcohol, an aminoacid or an aminoacid derivative. The N-nitrosocarbamoyl azide is obtained by reacting the corresponding alkylcarbamoyl azide with nitrogen tetroxide in the cold. The alkylcarbamoyl azide is obtained by reacting the corresponding isocyanate with an alkali metal azide.The invention further relates to novel nitroso ureas obtained thereby, to novel N-substituted alkyl-N-nitrosocarbamoyl azides, and to novel therapeutic compositions containing, as the active ingredient, the novel nitroso ureas.